Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Next Previous
Trial Profile

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozekibart (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Folinic acid; Irinotecan; Pemetrexed; Temozolomide
  • Indications Adenocarcinoma; Chondrosarcoma; Colorectal cancer; Ewing's sarcoma; Gastric cancer; Malignant-mesothelioma; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Inhibrx

Most Recent Events

  • 21 Jan 2025 According to an Inhibrx Biosciences media release, from the Phase 1 preliminary results, company has initiated a new expansion cohort to validate these findings in a more uniform patient population. The cohort is expected to enroll up to 50 patients, each with two to three prior lines of systemic therapy, and data are anticipated in Q3 2025.
  • 21 Jan 2025 According to an Inhibrx Biosciences media release, preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma were published at the American Society of Clinical Oncology (ASCO) Gastrointestinal Annual Cancers Symposium.
  • 21 Jan 2025 Results presented in the Inhibrx Biosciences Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top